Industry Survey: FDA Regs Driving VC Investment Overseas
This article was originally published in The Gray Sheet
Executive Summary
An estimated 42% of U.S. venture capital firms will reduce their medical device sector investments over the next three years due to a perception that FDA regulations are cost-prohibitive, arbitrary and cumbersome, according to the latest industry survey.
You may also be interested in...
On Eve Of User Fee Reform, Some Minnesota Firms Signal Skepticism
A survey of Minnesota device executives released last week closely aligns with previous industry polls, but the timing is notable: it comes just as Congress is completing passage of a user fee reauthorization bill championed by national device groups.
Start-Up FDA? CDRH Seeks Entrepreneurial Spirit With New “In-Residence” Program
CDRH is hoping to inject a dose of start-up-firm mentality into its processes with the official launch last week of the entrepreneurs-in-residence pilot program as part of a broader FDA push to highlight its “innovation” bona fides.
Start-Up FDA? CDRH Seeks Entrepreneurial Spirit With New “In-Residence” Program
CDRH is hoping to inject a dose of start-up-firm mentality into its processes with the official launch last week of the entrepreneurs-in-residence pilot program as part of a broader FDA push to highlight its “innovation” bona fides.